Trial Profile
A Multicenter, Open Label, Long-Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis
- 07 May 2012 Planned number of patients changed from 216 to 245 as reported by ClinicalTrials.gov.
- 22 Mar 2012 Actual patient number 314 added as reported by ClinicalTrials.gov.
- 22 Mar 2012 Actual initiation date changed from 1 Jul 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.